

# Financial Tear Sheet

## Corporate Profile

Lion Biotechnologies is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). This approach, also known as adoptive T-cell therapy, was developed by Dr. Steven A. Rosenberg at the National Cancer Institute. In Phase 2 clinical trials conducted at the NCI, 56% and 24% of patients treated with this technology achieved objective and complete response criteria, respectively.

Our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma.

In addition to metastatic malignant melanoma, carcinoma of the head and neck and cervical cancer our TIL therapy technology is potentially applicable to many other tumor types, including ovarian, breast, bladder, colorectal and other cancers. As we continue advancing our current clinical programs through the introduction of manufacturing and logistical efficiencies aimed at decreasing production time and optimizing distribution processes, we aim to establish TIL therapy as a revolutionary, accessible, mainline cancer therapy.

## Primary IR Contact

### **Stern Investor Relations, Inc.**

Sarah McCabe

Phone: 212-362-1200

E-mail:

[sarah@sternir.com](mailto:sarah@sternir.com)

## Stock Performance

### LBIO (Common Stock)

Exchange NASDAQ (US Dollar)

Price **\$7.10**

Change (%) **▲ 0.40 (5.97%)**

Volume 174,600

52 Week High \$9.58

52 Week Low \$4.90

Market Cap \$417,753,308

Rolling EPS -1.96

PE Ratio 0

Shares Outstanding 62,351,240

Data as of June 23, 2017 1:39 p.m. ET



## Recent Headlines

June 5, 2017

[Lion Biotechnologies Announces Updated Data at 2017 American Society of Clinical Oncology \(ASCO\) Annual Meeting from Ongoing LN-144 Phase 2 Clinical Trial](#)

June 1, 2017

[Lion Biotechnologies Announces First Patient Dosed in Phase 2 Trial of LN-145 for Head and Neck Cancer](#)

May 30, 2017

[Lion Biotechnologies to Present at Jefferies 2017 Healthcare Conference](#)

## Upcoming Events

There are currently no events scheduled.

## SEC Filings

Filing Date	Form
June 5, 2017	4
June 5, 2017	4
June 5, 2017	4
June 5, 2017	4

## Corporate Governance

Data provided by Nasdaq. Minimum 15 minutes delayed.

---

© 2017 Lion Biotechnologies, Inc. All Rights Reserved.